Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR), Amphastar Pharmaceuticals (AMPH) and COMPASS Pathways (CMPS)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Schrodinger (SDGR), Amphastar Pharmaceuticals (AMPH) and COMPASS Pathways (CMPS).
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Schrodinger (SDGR)
In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Schrodinger. The company’s shares closed last Wednesday at $15.94.
According to TipRanks.com, Hewitt is a 4-star analyst with an average return of
Schrodinger has an analyst consensus of Strong Buy, with a price target consensus of $20.25.
See today’s best-performing stocks on TipRanks >>
Amphastar Pharmaceuticals (AMPH)
Needham analyst Serge Belanger maintained a Hold rating on Amphastar Pharmaceuticals today. The company’s shares closed last Wednesday at $18.69.
According to TipRanks.com, Belanger is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Amphastar Pharmaceuticals with a $20.40 average price target, which is a 2.2% upside from current levels. In a report issued on June 26, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $23.00 price target.
COMPASS Pathways (CMPS)
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on COMPASS Pathways, with a price target of $70.00. The company’s shares closed last Wednesday at $13.14.
According to TipRanks.com, Trucchio is a top 100 analyst with an average return of
COMPASS Pathways has an analyst consensus of Strong Buy, with a price target consensus of $24.43, representing a 91.3% upside. In a report released today, TipRanks – Google also upgraded the stock to Buy with a $14.50 price target.
Read More on SDGR:
Disclaimer & DisclosureReport an Issue
- Schrödinger Gains $57 Million From Ajax Acquisition Deal
- Schrödinger Shareholders Expand Equity Plan, Elect Directors
- Schrodinger reports inducement grants under Nasdaq listing rule
- Schrödinger Finalizes Transition Terms for Former Commercial Chief
- Private Markets: Cognition AI raises $1B, Modal secures $355M
